Baker Avenue Asset Management, LP
Position in RPRX — Royalty Pharma plc
CIK 1432529
SAN FRANCISCO, CA
Position in RPRX
as of Jun 30, 2026
· filed Jul 28, 2026
Position Value
$391,985
+$62,048 QoQ
Shares Held
6,991
+1.6% QoQ
Ownership
0.001%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#427
of 641 holders
Holding Since
Dec 2022
6 quarters on record
Voting authority
Sole 42%
Shared 0%
None 58%
Common Shares in RPRX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Baker Avenue Asset Management, LP holds $4,381,815 across 10 Biotechnology names. RPRX ranks #5 (8.9% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VCEL |
Vericel Corp
|
26,219 | $1,166,483 | |
| 2 | PCVX |
Vaxcyte, Inc.
|
13,279 | $771,908 | |
| 3 | JAZZ |
Jazz Pharmaceuticals plc
|
2,447 | $589,653 | |
| 4 | REGN |
Regeneron Pharmaceuticals, Inc.
|
931 | $580,515 | |
| 5 | RPRX |
Royalty Pharma plc
This page
|
6,991 | $391,985 | |
| 6 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
653 | $324,364 | |
| 7 | INCY |
Incyte Corp
|
2,148 | $243,497 | |
| 8 | EXEL |
Exelixis, Inc.
|
3,885 | $211,382 |
All Filings in RPRX
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $391,985 | 6,991 | Shares | Sole | 2026-07-28 | |
| 2026-03-31 | $329,937 | 6,878 | Shares | Sole | 2026-05-12 | |
| 2023-09-30 | $3,229 | 119 | Shares | Sole | 2023-11-15 | |
| 2023-06-30 | $1,659 | 54 | Shares | Sole | 2023-08-14 | |
| 2023-03-31 | $1,297 | 36 | Shares | Sole | 2023-05-16 | |
| 2022-12-31 | $1,501 | 38 | Shares | Sole | 2023-02-14 | |
| No filing history on record for this holder in this stock. | ||||||